/ Cytopoint

Cytopoint logo

Veterinary Professionals

CYTOPOINT is an injection that controls chronic dog itch for 4 to 8 weeks*

CYTOPOINT is a safe, effective, long-lasting treatment for chronic itch due to allergic or atopic dermatitis. It is an injection that is given by your veterinarian that targets itch at its source.

CYTOPOINT works like your dog’s own immune system. It is specifically designed to target and neutralize one of the main proteins that send itch signals to your dog’s brain that triggers scratching, licking, and chewing. CYTOPOINT blocks signals that trigger itch, so the constant scratching can stop, and red, irritated skin can heal. In fact, in a study, CYTOPOINT helped damaged skin begin to heal within 7 days.1

Relief of dog itch at long last!

Just one CYTOPOINT injection starts controlling itch within one day and provides relief that lasts for 4 to 8 weeks.*1 That means your dog may be able to go as long as 8 weeks1 between injections.

One CYTOPOINT® helps control itch for 4 to 8 weeks.*
CYTOPOINT works with your dog’s own immune system to clock the signals that trigger itch.²,³

How does CYTOPOINT work?

CYTOPOINT is not like traditional pharmaceutical treatments for chronic itch. It is a biological medication (a protein, not a chemical) that works like your dog’s own immune system to block the signals that trigger itch.2,3

The itch cycle in dogs with chronic itch

The itch cycle in dogs with chronic itch due to atopic dermatitis.

How will you know when it’s time for another CYTOPOINT injection?

Your veterinarian may schedule a return visit 4 weeks after the first injection. But every dog is different, so monitoring your dog’s itch is important. If you notice your dog's itch acting up again, it's a sign that you should schedule your next CYTOPOINT injection. The CYTOPOINT Itch Tracker can help. It's simple to use and downloadable.

CYTOPOINT is safe for dogs of all ages

CYTOPOINT is safe to use in dogs of any age. It can also be used in dogs on many other commonly used medications, or dogs with other diseases.6 In fact, a clinical study showed dogs receiving CYTOPOINT had no more side effects than dogs receiving placebo (injections without medication).6 And since CYTOPOINT is not a chemical-based treatment, it does not put pressure on the liver and kidneys.

With CYTOPOINT, you gain the comfort of knowing every injection is delivered effectively and safely during an office visit. Your veterinarian administers a complete dose that helps relieve chronic dog itch for up to 8 weeks,* making the treatment of allergic skin condition easier for you to manage.

How long will my dog need CYTOPOINT treatment?

Some dogs have year-round disease and may need continuous treatment with CYTOPOINT, whereas other dogs may only need CYTOPOINT when itch flares during allergy season. You and your veterinarian should decide together what is best for your dog’s specific situation.

See how Exeland got long-lasting relief of chronic itch with CYTOPOINT

See Exeland’s story and how CYTOPOINT® provided long-lasting itch relief

Learn about chronic dog itch and treatment

*Repeat administration every 4 to 8 weeks as needed in the individual patient.1

References: 1. Data on file, Study Report No. C863R-US-12-018, Zoetis Inc. 2. Gonzales AJ, Humphrey WR, Messamore JE, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol. 2013;24(1):48-53. doi:10.1111/j.136S-3164.2012.01098.x. 3. Olivry T, Bäumer W. Atopic itch in dogs: pharmacology and modeling. In: Cowan A, Yosipovitch G, eds. Pharmacology of Itch, Handbook of Experimental Pharmacology. 2015:357-369. 4. Marsella R, Sousa CA, Gonzales AJ, et al. Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis. J Am Vet Med Assoc. 2012;241(2):194-207. doi:10.2460/javma.241.2.194. 5. Olivry T, DeBoer DJ, Favrot C, et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol. 2010;21(3):233-248. doi:10.1111/j.1365-3164.2010.00889.x. 6. Data on file, Study Report No. C961R-US-13-051, Zoetis Inc.